IP Library › Granted Patent US 10,925,932
Granted Patent B2
US 10,925,932 · App. 15/611,296 · Granted Feb 23, 2021

Serum albumin-binding fibronectin type III domains

Inventors: Michael Diem (Spring House, PA); Steven Jacobs (Spring House, PA); Karyn O'Neil (Spring House, PA); Thomas Rutkoski (Spring House, PA)
Assignee: Janssen Biotech, Inc.
A61K38/39A61K47/549C07K14/78C07K16/18C07K16/40A61K2039/505C07K2317/94C07K2318/20C07K2319/30C07K2319/31C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,925,932
App. No.
15/611,296
Granted
Feb 23, 2021
Kind
B2
Abstract

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Claims (16)

1. A protein comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, or 8 substitutions as compared to the amino acid sequence of SEQ ID NO: 51.

2. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 51.

3. The protein of claim 1 , wherein the protein is at least 95%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 51.

4. The protein of claim 1 , wherein the protein comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, or 8 substitutions when compared to the amino acid sequence of SEQ ID NO: 51.

5. A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

6. A kit comprising the protein of claim 1 .

7. A molecule comprising a first domain and a second domain, wherein the first domain comprises the protein of claim 1 and the second domain is a molecule that binds to a target protein other than human serum albumin.

8. The protein of claim 1 , wherein the protein is at least 95% identical to the amino acid sequence of SEQ ID NO: 51.

9. The protein of claim 1 , wherein the protein is at least 97% identical to the amino acid sequence of SEQ ID NO: 51.

10. The protein of claim 1 , wherein the protein is at least 98% identical to the amino acid sequence of SEQ ID NO: 51.

11. The protein of claim 1 , wherein the protein is at least 99% identical to the amino acid sequence of SEQ ID NO: 51.

12. The protein of claim 1 , wherein the protein comprises the amino acid sequence of SEQ ID NO: 51.

13. A method of detecting the presence of human serum albumin in a biological sample comprising contacting the biological sample with the protein of claim 1 and determining the binding of the biological sample to the protein.

14. A protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-53.

15. A protein comprising the amino acid sequence of SEQ ID NO: 52.

16. A protein comprising the amino acid sequence of SEQ ID NO: 53.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2019
From: DIEM, MICHAEL; JACOBS, STEVEN; O'NEIL, KARYN; RUTKOSKI, THOMAS
To: JANSSEN BIOTECH, INC.
Reel/Frame 049736/0388 →
Continuity (2)
Provisional Application 62345190 · Jun 3, 2016
Related Publication 20170348397A1 · Dec 7, 2017
Cited By (5)
US 12,239,710 US 12,351,619 US 12,491,255 US 12,589,159 US 12,599,652